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Comprehensive Association Analysis of Candidate
Genes for Generalized Vitiligo Supports XBP1,
FOXP3, and TSLP
Stanca A. Birlea1,2, Ying Jin1,3, Dorothy C. Bennett4, Deborah M. Herbstman5, Margaret R. Wallace5,
Wayne T. McCormack6, E. Helen Kemp7, David J. Gawkrodger8, Anthony P. Weetman7, Mauro Picardo9,
Giovanni Leone10, Alain Taı¨eb10, Thomas Jouary10, Khaled Ezzedine10, Nanja van Geel11, Jo Lambert11,
Andreas Overbeck12, Pamela R. Fain1,3,13 and Richard A. Spritz1,3
We previously carried out a genome-wide association study of generalized vitiligo (GV) in non-Hispanic whites,
identifying 13 confirmed susceptibility loci. In this study, we re-analyzed the genome-wide data set (comprising
1,392 cases and 2,629 controls) to specifically test association of all 33 GV candidate genes that have previously
been suggested for GV, followed by meta-analysis incorporating both current and previously published data.
We detected association of three of the candidate genes tested: TSLP (rs764916, P¼ 3.0E-04, odds ratio
(OR)¼ 1.60; meta-P for rs3806933¼ 3.1E-03), XBP1 (rs6005863, P¼ 3.6E-04, OR¼ 1.17; meta-P for rs2269577¼ 9.5E-
09), and FOXP3 (rs11798415, P¼ 5.8E-04, OR¼ 1.19). Association of GV with CTLA4 (rs12992492, P¼ 5.9E-05,
OR¼ 1.20; meta-P for rs231775¼ 1.0E-04) seems to be secondary to epidemiological association with other
concomitant autoimmune diseases. Within the major histocompatibility complex (MHC), at 6p21.33, association
with TAP1-PSMB8 (rs3819721, P¼ 5.2E-06) seems to derive from linkage disequilibrium with major primary
signals in the MHC class I and class II regions.
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INTRODUCTION
Vitiligo is the most frequent pigmentation disorder, with a
prevalence ofB0.38% in Caucasians. In generalized vitiligo
(GV), the predominant form of the disorder, patches of
depigmented skin result from autoimmune destruction
of melanocytes (Birlea et al., 2010). GV is a ‘‘complex
disorder,’’ involving combinatorial pathogenic effects of
multiple susceptibility genes and unknown environmental
triggers (Spritz, 2010). Moreover, patients with GV and also
their close relatives have elevated frequencies of certain other
autoimmune diseases (Alkhateeb et al., 2003; LaBerge et al.,
2005), suggesting that these autoimmune diseases involve
shared susceptibility factors.
Numerous genetic studies of biological candidate genes
for GV have been published (reviewed in Spritz (2010)).
Whereas some genes, such as HLA and PTPN22, have had
consistent support from multiple studies, most other genes
have not. Many studies of the latter group have been limited
by small sample sizes and thus insufficient power, failure
to adequately correct for multiple testing, and very likely
population stratification artifacts, all of which greatly increase
the risk of false-positive ‘‘associations’’ (Hirschhorn et al.,
2002; Freedman et al., 2004); accordingly, over the past few
years, candidate gene studies have been largely replaced by
genome-wide association studies (GWASs), which can avoid
or control for these causes of false association.
We recently carried out a GWAS of GV in non-Hispanic
white subjects, identifying and confirming at least 13 different
loci that contribute to GV risk, almost all of which have
immunoregulatory functions (Jin et al., 2010a, b); 2 of these
loci and 1 additional signal in the major histocompatibility
complex (MHC) were also identified in a Chinese GWAS of
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GV (Quan et al., 2010). To detect additional GV suscept-
ibility loci that were not identified by the GWAS, we took
advantage of our very large genome-wide data set, which has
been subjected to rigorous data quality control and correction
for population stratification, to specifically test for association
of 33 biological candidate genes that have been previously
implicated in GV (ACE, AIRE, CAT, CD4, CLEC11A, COMT,
CTLA4, C12orf10, DDR1, EDN1, ESR1, FAS, FBXO11,
FOXD3, FOXP3, GSTM1, GSTT1, IL1RN, IL10, KITLG,
MBL2, NFE2L2, PDGFRA-KIT, PTGS2, STAT4, TAP1-PSMB8,
TGFBR2, TNF, TSLP,TXNDC5, UVRAG, VDR, and XBP1;
Supplementary Table S1 online), followed by a meta-analysis
incorporating both the current and available previously
published data, when possible. Three of the loci tested
(namely FOXP3, TSLP, and XBP1) showed evidence of
primary association with GV, and the meta-analysis strongly
supported XBP1 as a true GV susceptibility locus. A fourth
locus, CTLA4, seems to be secondarily associated with GV,
deriving from primary association with other autoimmune
diseases that are epidemiologically associated with GV. The
apparent association of TAP1-PSMB8 with GV is secondary to
linkage disequilibrium (LD) with primary associated loci
located elsewhere in the MHC class I and class II gene
regions.
RESULTS
The 33 gene regions and candidate single-nucleotide poly-
morphisms (SNPs) analyzed are shown in Table 1. Our
sample set of non-Hispanic whites (N¼1,392 cases,
N¼2,629 controls; see Jin et al. (2010a)) provided 80%
power to detect significant association at odds ratios (ORs)
X1.21, 1.22, and 1.26 for corresponding minor allele
frequencies of 0.5, 0.3, and 0.2, respectively, assuming a
multiplicative model. P-values for association were consid-
ered using two different Bonferroni multiple-testing adjusted
significance thresholds. The first, less conservative, threshold
was based on the 33 loci tested (0.05/33; Po1.52E-03 (0.05/
33). The second, more stringent, threshold was based on 80
blocks of LD tested, calculated using D 0 (0.05/80; Po6.25E-
04). For each allelic association, we calculated a meta-
analysis P-value (referred to as ‘‘meta-P ’’ herein) on the basis
of all available current and previously published data, in most
cases imputing the previously reported SNP in the current
genome-wide data set. Many of these previous reports did not
apply appropriate multiple-testing correction; for each of
these, we calculated and applied the requisite correction.
ACE
In 120 GV cases and 429 controls from Korea, Jin et al.
(2004b) reported an association with the ACE region
insertion–deletion (indel) rs1799752 (ACE I/D) (allelic
P¼1.2E-02). Three subsequent studies failed to replicate this
association: a UK study of 106 non-Hispanic white cases and
174 controls (Akhtar et al., 2005), an Indian study of 125
cases and 156 controls (Dwivedi et al., 2008), and a Turkish
study of 48 cases and 50 controls (Pehlivan et al., 2009).
Indel rs1799752 is not in HapMap, but is in complete LD
(D 0 ¼1, r2¼0.86) with rs4343 (Abdollahi et al., 2008). In this
study, we observed no association with rs4343 (allelic
P¼0.17); however, a meta-analysis of rs4343 and published
data for rs1799752 could not be performed. Overall, we
observed no association of any of 24 SNPs (14 imputed)
spanning the ACE region (chr17:61,544,434-61,579,979).
AIRE
Genetic linkage analysis of non-Hispanic white GV families
identified a minor linkage peak in 21q that includes AIRE
(Fain et al., 2003), but re-analysis of the same families found
no association of GV with seven SNPs spanning the AIRE
region (Jin et al., 2007). In a small UK non-Hispanic white
cohort of 86 cases and 63 controls, Tazi-Ahnini et al. (2008)
reported an association of vitiligo with the AIRE-synonymous
SNP rs1800521 (allelic P¼ 1.4E-05), which was not included
in the previous linkage study and is not in HapMap. In this
study, we observed no association of any of the 29 SNPs (22
imputed) spanning the AIRE region (chr21:45,695,763-
45,723,110), including the 7 SNPs studied previously
(Jin et al., 2007).
CAT
In a US non-Hispanic white cohort of 230 GV cases and 188
controls, Casp et al. (2002) reported genotypic (P¼1.6E-02,
Bonferroni-adjusted P¼3.2E-02), but not allelic (P¼0.18,
Bonferroni-adjusted P¼0.36), association of the CAT SNP
rs769217, and in a UK non-Hispanic white cohort of 166
vitiligo cases and 169 controls, Gavalas et al. (2006) also
reported association (allelic P¼2.2E-02, genotypic P¼3.0E-
02) of rs769217. However, studies of rs769217 from Korea
(Park et al., 2006), India (Em et al., 2007), and China (Liu
et al., 2010) found no association. In this study, we observed
no association with rs769217 (allelic P¼0.21, genotypic
P¼0.26), and the meta-analysis of SNP rs769217 demon-
strated a consistent high-risk allele across the six studies, but
failed to achieve the study significance threshold, either
overall (meta-P¼ 2.1E-02, OR¼1.08) or in an analysis
limited to the three non-Hispanic white cohorts (meta-
P¼0.12, OR¼1.09). Liu et al. (2010) reported an association
with 50-flanking SNP rs7943316 (allelic P¼1.0E-03, geno-
typic P¼6.0E-03), but we found no association with
rs7943316 (allelic P¼0.45, meta-P¼2.2E-02, OR¼1.10).
Overall, we observed no association with any of the 48 SNPs
(30 imputed) spanning the CAT region (chr11:34,450,478-
34,498,603).
CD4
In 144 GV cases and 144 controls from Iran, Zamani et al.
(2009) reported an association with a pentanucleotide
variable number of tandem repeats polymorphism (VNTR)
(CD4-1188) (Bonferroni-corrected P¼ 2.0E-02 for allele A4
and Bonferroni-corrected P¼ 1.0E-02 for genotype A4/X). In
European non-Hispanic whites, VNTR CD4-1188 is in strong
LD with rs2855534 (Kristiansen et al., 2004), which in this
study did not achieve the study significance threshold
(P¼5.0E-02). Overall, we observed no association with any
of the 28 SNPs (14 imputed) spanning the CD4 region
(chr12:6,872,512-6,939,850).
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CLEC11A
In 51 GV cases and 118 controls from Taiwan, Lan et al.
(2009) reported association with rs7246355 and rs13866
(false-discovery rate-adjusted P¼ 3.2E-02 for both SNPs). In
this study, we observed no association with rs7246355
(allelic P¼0.48); rs13866 is not in HapMap and thus cannot
be imputed. Overall, we observed no association of any of
the 12 SNPs (6 imputed) spanning the CLEC11A region
(chr19:51,216,605-51,233,979).
COMT
In 749 GV cases and 763 controls from China, Li K et al. (2009)
reported an association with nonsynonymous SNP rs4680
(genotypic P¼ 3.0E-03, allelic P¼ 1.1E-03). In this study, we
observed no association with rs4680 (genotypic P¼0.47, allelic
P¼ 0.14, meta-P¼ 0.26, OR¼1.03) or with any of the 20 SNPs
spanning the COMT region (chr22:19,919,263-19,962,496).
CTLA4
Most CTLA4 association studies have assayed the nonsynon-
ymous SNP rs231775 (þ 49 A/G). In 74 non-Hispanic white
cases and 173 controls, Kemp et al. (1999) reported an
association of vitiligo with a CTLA4 intragenic microsatellite in
strong LD with rs231775 (uncorrected P¼ 2.0E-02), princi-
pally in the subgroup of cases with other concomitant
autoimmune diseases (uncorrected P¼ 1.0E-04). Similar find-
ings were reported in two case–control studies from Turkey
(Itirli et al., 2005; Pehlivan et al., 2009). Similarly, Blomhoff
et al. (2005) observed association only in the subgroup of
European non-Hispanic white GV cases with other auto-
immune diseases (rs231775, rs3087243, rs11571302, and
rs7565213 uncorrected allelic P¼8.0E-02, P¼ 3.0E-02,
P¼2.0E-02, and P¼ 1.0E-02, respectively). In contrast, three
other studies in non-Hispanic whites found no association for
all comparisons: a family-based study (LaBerge et al., 2008)
and two case–control studies (Birlea et al., 2009); a fourth
study, in Indians (Deeba et al., 2010), found no association of
CTLA4 with nonsegmental vitiligo. Meta-analysis of all studies
of GV in non-Hispanic whites indicated significant association
of rs231775 (and near significance for other SNPs in LD) in the
subgroup of GV cases with other concomitant autoimmune
diseases (Birlea et al., 2009).
In this study, rs231775 was associated with GV in both the
all-cases group (P¼2.6E-04, meta-P¼2.5.0E-04, OR¼1.15)
and in the subgroup of cases with other autoimmune diseases
(P¼1.2E-04, meta-P¼4.4E-06, OR¼1.37). In contrast, the
study significance threshold was not achieved for the
subgroup of cases with only vitiligo (P¼2.0E-02, meta-
P¼6.0E-02, OR¼1.10). Overall, we analyzed 104 SNPs (87
imputed) spanning the CTLA4 region (chr2:204,694,351-
204,799,697) and observed association across multiple SNPs
(Supplementary Figure S1 online) in both the all-cases group
and the subgroup of cases with other autoimmune diseases,
both groups showing maximum association with the CTLA4
promoter region SNP rs12992492 (P¼5.9E-05, OR¼1.20
and P¼7.3E-05, OR¼ 1.36, respectively). By contrast, no
CTLA4 region SNP achieved the study significance threshold
in the subgroup of patients with isolated GV without other
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autoimmune diseases (Supplementary Figure S1 online).
Furthermore, comparison of the subsets of GV cases
with versus without other autoimmune diseases was sig-
nificant for both rs231775 (P¼ 2.1E-02, meta-P¼1.3E-02)
and rs12992492 (P¼2.9E-02). Taken together, these results
support previous conclusions that association of CTLA4 with
GV is secondary, driven by primary genetic association of
CTLA4 with other autoimmune diseases that are epidemio-
logically associated with vitiligo.
C12orf10
In 124 GV cases and 325 controls from Estonia, Philips et al.
(2010) reported an association with C12orf10 promoter SNP
rs1465073 (allelic P¼3.8E-02). In this study, we observed no
association of GV with rs1465073 (allelic P¼ 0.23), and the
meta-analysis was not significant (meta-P¼0.27, OR¼1.03).
Overall, we observed no association of GV with any of
the 11 SNPs (8 imputed) spanning the C12orf10 region
(chr12:53,683,470-53,705,964).
DDR1
In 220 cases and 409 controls from Korea, Kim et al. (2010)
found no association of vitiligo with any of 6 DDR1 markers.
However, in 212 trios from Brazil, Silva de Castro et al.
(2010), reported association of rs2267641 (allelic P¼1.0E-
02, Bonferroni-corrected P¼3.0E-02), rs4618569 (P¼2.0E-
02, Bonferroni-corrected P¼6.0E-02), and rs1049623
(P¼5.0E-02, Bonferroni-corrected P¼0.15). These investi-
gators also reported genotypic association of rs2267641 in an
independent Brazilian cohort of 134 cases and 134 controls
(genotypic P¼4.0E-02, allelic P¼0.87); however, that result
was rendered not significant by application of appropriate
multiple-testing correction (Bonferroni-corrected genotypic
P¼0.12). In this study, we observed no association with
rs2267641 (allelic P¼0.32, genotypic P¼ 0.89), and the
meta-analysis was also not significant (allelic meta-P¼0.27,
OR¼1.04; genotypic meta-P¼8.0E-02, OR¼1.10). Overall,
we observed no association with any of the 41 SNPs (14
imputed) spanning the DDR1 region (chr6:30,486,465-
30,872,931).
EDN1
In 312 cases and 313 controls from Korea, Kim et al. (2007)
reported association with an EDN1 haplotype defined by
rs2071942 (intron 4 G/A) and rs5370 (exon 5 G/T) (P¼ 3.1E-08).
A study of 51 cases and 118 controls from Taiwan (Lan et al.,
2009) did not replicate association with either of these SNPs or
with the rs2071942–rs5370 haplotype (false-discovery rate-
adjusted allelic P¼ 0.78 for each SNP). We could not test
rs2071942–rs5370 haplotypes, as rs2071942 is not in Hap-
Map; however, we observed no association with rs5370
(allelic P¼0.24, meta-P¼ 0.17, OR¼1.05) or with any
of the 30 SNPs (17 imputed) spanning the EDN1 region
(chr6:12,280,529-12,302,426).
ESR1
In 120 GV cases and 254 controls from Korea, Jin et al.
(2004a) reported an association with the ESR1 intronic SNP
rs2234693 (allelic P¼3.4E-02). In this study, we observed no
association with rs2234693 (allelic P¼ 0.20, meta-P¼0.38,
OR¼1.01) or with any of the 73 SNPs (24 imputed) spanning
the ESR1 region (chr6:152,118,454-152,429,406).
FAS
In 750 cases and 756 controls from China, Li et al. (2008) and
Li M et al. (2009) reported an association of vitiligo with the
FAS 50-flanking SNP rs2234767 (1377A4G) (allelic
P¼7.0E-03, genotypic P¼6.0E-03). SNP rs2234767 is not
in HapMap, but is correlated (D 0 ¼ 0.89, r2¼0.66) with
rs1800682 (Kim et al., 2009). In this study, we observed no
association with rs1800682 (allelic P¼ 7.1E-02, genotypic
P¼0.17) or with any of the 30 SNPs (20 imputed) spanning
the FAS region (chr10:90,740,288-90,780,541).
FBXO11-MSH6
The involvement of FBXO11 (previously, VIT1) in vitiligo was
suggested on the basis of differential expression analysis
(Le Poole et al., 2001). Putative mutations in the adjacent
MSH6 gene were reported in a single patient with early-onset
colorectal cancer, systemic lupus erythematosus, and vitiligo
(Rahner et al., 2008). In this study, we observed no
association with any of 12 SNPs spanning the FBXO11-
MSH6 region (chr2:48,029,061-48,142,814).
FOXD3
Alkhateeb et al. (2002) found linkage of GV with microsatellite
markers in chromosome 1p31.3 in a multi-generation, non-
Hispanic white family with GV and other autoimmune diseases,
and subsequently reported cosegregation of GV with a unique
variant (rs41285370) in the 50-flanking region of FOXD3
(639G4T) (Alkhateeb et al., 2005). SNP rs41285370 is not
in HapMap and thus cannot be imputed; accordingly, we
analyzed 10 SNPs (7 imputed) spanning the FOXD3 region
(chr1:63,778,730-63,795,797) and observed no association.
FOXP3
FOXP3 is the defective gene in the X-linked recessive
immunodysregulation, polyendocrinopathy, and enteropathy
multiple autoimmune disease syndrome (OMIM #304790),
which can include GV. We analyzed 37 SNPs (30 imputed)
across the FOXP3 region (chrX:49,093,528-49,373,620),
observing tight LD across a 242-kb block that includes
FOXP3, PPP1R3F, GAGE10, and GAGE1 (Supplementary
Figure S2A online). Within FOXP3, the greatest significance
was for promoter region SNP rs3761547 (P¼1.8E-03,
OR¼1.23). However, within the LD block, the greatest
significance was for rs11798415 within GAGE10 (P¼5.8E-
04, OR¼ 1.19) and for rs5906843 within GAGE1 (P¼6.2E-
04). Forward stepwise regression analysis of the four most-
strongly associated markers in the region (namely
rs11798415, rs5906843, rs5906777, and rs4824755) indi-
cated that all associations are secondary to rs11798415.
GSTM1
In 310 GV cases and 549 controls from Korea, Uhm et al.
(2007) reported an association with a GSTM1 region indel
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polymorphism (genotypic P¼1.2E-06, OR¼2.04, Bonferroni-
corrected P¼2.5E-06). A subsequent study in a Chinese
cohort failed to replicate this association (Liu et al., 2009).
This GSTM1 indel variant is not in HapMap; accordingly,
we analyzed 4 SNPs (2 imputed) spanning the GSTM1
region (chr1:110,220,418-110,241,366) and observed no
association.
GSTT1
In 749 GV cases and 763 controls from China, Liu et al.
(2009) reported an association with indel rs2234953
(GSTT1þ /) (genotypic P¼1.1E-03, Bonferroni-adjusted
genotypic P¼3.3E-03), although a study of 310 cases and
449 controls from Korea found no association with the same
marker (Uhm et al., 2007). Indel rs2234953 is not in
HapMap; accordingly, we analyzed 3 SNPs (all imputed)
spanning the GSTT1 region (chr22:24,371,141-24,394,284)
and found no evidence of association.
IL1RN
In 48 cases and 50 controls from Turkey, Pehlivan et al.
(2009) reported an association with an IL1RN intronic VNTR
polymorphism (allelic P¼1.6E-02, genotypic P¼ 1.5E-02), a
result rendered not significant by appropriate multiple-testing
correction (allelic and genotypic P¼6.0E-02). In the
European non-Hispanic white population, this VNTR is in
complete LD with SNP rs419598 (IL1RNþ 2018) (Hutyrova´
et al., 2002). In this study, we observed no association with
rs419598 (allelic P¼ 0.48, genotypic P¼0.50) or with any of
the 54 SNPs (46 imputed) spanning the IL1RN region
(chr2:113,875,138-113,896,592).
IL10
In 83 GV cases and 101 controls from Saudi Arabia, Abanmi
et al. (2008) reported association with IL10 50-flanking SNPs
rs1800871 (819C/T; genotypic P¼2.0E-02) and rs1800872
(592C/A) (which are in perfect LD). In this study, we
observed no association of GV with either rs1800871 or
rs1800872 (genotypic P¼ 0.49), and the meta-analysis was
also not significant (meta-P¼0.27, OR¼1.03). Overall, we
observed no association with any of the 20 SNPs (12
imputed) spanning the IL10 region (chr1:206,935,948-
206,955,839).
KITLG
In 51 GV cases and 118 controls from Taiwan, Lan et al.
(2009) reported an association with the intronic SNP
rs11104947 (false-discovery rate-adjusted P¼ 3.6E-02). In
this study, rs11104947 was not significant (P¼6.0E-02,
meta-P¼1.4E-02, OR¼1.17), and we observed no associa-
tion with any of the 34 SNPs (28 imputed) spanning the
KITLG region (chr12:88,881,569-88,984,238).
MBL2
In 40 GV cases and 50 controls from Turkey, Onay et al.
(2007) reported an association with the nonsynonymous
MBL2 SNP rs1800450 (allelic P¼1.0E-04, genotypic
P¼1.0E-03). A study of 92 cases and 94 controls from India
(Dwivedi et al., 2009) failed to replicate this association. In
this study, we observed no association of GV with rs1800450
(allelic P¼0.17, genotypic P¼0.20) or with any of
the 15 SNPs spanning the MBL2 region (chr10:54,520,
141-54,541,460).
NFE2L2
In 300 GV cases and 300 controls from China, Guan et al.
(2008) reported an association with the NFE2L2 50-flanking
SNP rs6721961 (650C/A) (allelic P¼2.1E-05, genotypic
P¼1.8E-04). SNP rs6721961 is not in HapMap and thus
cannot be imputed; accordingly, we analyzed 24 SNPs (19
imputed) spanning the NFE2L2 region (chr2:178,090,
034-178,139,859) and found no association.
PDGFRA-Kit
Xu et al. (2010) followed up a GV linkage signal (AIS4) at
4q12 detected in Chinese GV families (Chen et al., 2005) by
sequencing PDGRFA, identifying rare PDGRFA variants in
3.5% of familial GV cases versus 0.42% of controls (P¼8.0E-
03), with no significant difference (P¼5.3E-02) in sporadic
vitiligo cases (1%) versus controls. In this study, we observed
no association with any of the 101 SNPs spanning the
PDGFRA-KIT region (chr4:55,085,263-55,611,5879). Never-
theless, genetic association studies have little power to detect
rare DNA sequence variants, and the majority of GV cases in
the current study are sporadic rather than familial.
PTGS2
In 755 GV cases and 774 controls from China, Li K et al.
(2009) reported an association with the PTGS2 50-flanking
SNP rs689466 (1195A4G) (allelic P¼ 1.4E-02, genotypic
P¼4.0E-03). In this study, we observed no association with
rs689466 (genotypic P¼ 0.10, allelic P¼0.16), and the meta-
analysis was not significant (meta-P¼0.27, OR¼1.03).
Overall, we observed no association with any of the
32 SNPs (25 imputed) spanning the PTGS2 region
(chr1:186,635,945-186,659,559).
STAT4
In 379 cases and 414 controls from China, Hu et al. (2010)
reported an association of STAT4 SNP rs7574865 (genotypic
P¼1.3E-02). In this study, rs7574865 did not achieve the
study significance threshold (genotypic P¼ 0.17, allelic
P¼2.5E-02); similarly, meta-analysis was not significant
(meta-P¼1.1E-02, OR¼ 1.13). Overall, we observed no
association with any of the 27 SNPs spanning the STAT4
region (chr2:191,889,306-192,025,925).
TAP1-PSMB8
TAP1 and PSMB8 (previously, LMP7) are in close juxtaposi-
tion in the MHC class II region. Casp et al. (2003) reported
association of vitiligo with TAP1-PSMB8 in two independent
US non-Hispanic white cohorts: the first 230 cases and
188 controls (rs1135216, allelic P¼ 3.4E-03, Bonferroni-
corrected P¼ 6.8E-03; genotypic P¼ 9.4E-03, Bonferroni-
corrected P¼ 1.9E-02) and the second a family-based
association study of 35 families (rs2071627, P¼5.7E-05,
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Bonferroni-corrected P¼ 1.1E-04). In this study, we observed
no association with rs1135216 (genotypic P¼0.19; allelic
P¼8.5E-02, meta-P¼0.33, OR¼1.03); SNP rs2071627 is
not in HapMap and thus cannot be imputed. Overall, we
tested 34 SNPs (15 imputed) spanning the TAP1-PSMB8
region (chr6:32,807,987-32,831,748), with the strongest
association observed for rs3819721 (P¼ 5.2E-06) and for
rs6924102 (P¼9.4E-05). However, as we previously demon-
strated two major independent association signals in the
MHC class I and class II regions (HLA-A-HCG9 rs12206499
and HLA-DRB1/DQA1 rs532098; Jin et al., 2010a), we tested
the association of rs3819721 and rs6924102 by nested
regression analysis accounting for LD with rs12206499 and
rs532098; this analysis indicated that the effects of TAP1-
PSMB8 region SNPs reflect LD with these primary MHC class
I and class II association signals.
TGFBR2
In 233 GV cases and 415 controls from Korea, Yun et al.
(2010) reported association with TGFBR2 SNPs rs2005061
(codominant P¼6.0E-04), rs3773645 (recessive P¼1.2E-02),
and rs3773649 (recessive P¼6.9E-03), all Bonferroni cor-
rected. In this study, we observed no association with any of
these SNPs, and meta-analysis was likewise generally not
significant (rs2005061 codominant P¼2.3E-02, meta-
P¼0.39, OR¼1.02; rs3773645 recessive P¼ 0.35, meta-
P¼0.28, OR¼1.03; and rs3773649 recessive P¼0.42,
meta-P¼9.0E-02, OR¼1.07). Overall, we observed no
association with any of the 66 SNPs (30 imputed) spanning
the TGFBR2 region (chr3:30,637,994-30,740,631).
TNF
In 176 cases and 545 controls from Iran, Namian et al. (2009)
reported a genotypic association of vitiligo with the TNF
promoter SNP rs1800629 (genotypic P¼ 4.0E-04, allelic
P¼0.28), whereas Yazici et al. (2006) observed no associa-
tion of vitiligo with rs1800629 in 61 cases and 123 controls
from Turkey. In this study, SNP rs1800629 was excluded
because it deviated significantly from Hardy–Weinberg
equilibrium in controls. Overall, we observed no association
with any of the 25 SNPs (18 imputed) spanning the TNF
region of the MHC (chr6:31,533,350-31,551,110). Several
SNPs in the neighboring LTA gene showed evidence of
association (rs1800683, P¼7.9E-05); however, nested re-
gression analysis comparing a model that included these LTA
SNPs and the two major independent MHC association
signals (HLA-A-HCG9 rs12206499 and HLA-DRB1/DQA1
rs532098; Jin et al., 2010a) indicated that the effects of LTA
SNPs reflect LD with these primary MHC class I and class II
association signals.
TSLP
In 160 GV cases and 568 controls from Korea, Cheong et al.
(2009) reported an association with the TSLP 50-flanking SNP
rs3806933 (847C4T) (allelic P¼1.7E-02, OR¼1.29,
genotypic P¼ 4.0E-03). In this study, we observed nominal
significance for rs3806933 (allelic P¼2.1E-02, OR¼1.10)
and for many neighboring SNPs (Supplementary Figure S2B
online), and meta-analysis of data for rs3806933 showed
improved significance (meta-P¼3.1E-03, OR¼1.13),
although the study significance threshold was not achieved.
However, among the 41 SNPs (29 imputed) analyzed
spanning the TSLP region (chr5:110,358,245-110,427,347),
we observed association of GV with the promoter SNP
rs764916 (P¼3.0E-4), and with a cluster of nearby SNPs,
located 6.5 kb upstream of the candidate SNP rs3806933
(Supplementary Figure S2B online). The difference in the
signal location in non-Hispanic whites versus Koreans may
reflect the greater density of SNPs tested in this study as well
as ethnic differences.
TXNDC5
In 230 GV cases and 417 controls from Korea, Jeong et al.
(2010a) reported an association with the TXNDC5 SNP
rs1043784 (codominant P¼3.5E-02). In this study, we
observed no association with rs1043784 (P¼0.34, meta-
P¼0.10, OR¼ 1.09) or with any of the 18 SNPs (11 imputed)
spanning the TXNDC5 region (chr6:7,876,754-7,921,041).
UVRAG
In 225 vitiligo cases and 439 controls from Korea, Jeong et al.
(2010b) reported association with a haplotype defined
by SNPs rs7933235 and rs1458836 (Bonferroni-corrected
P¼3.0E-02). In this study, we observed no association with
either of these SNPs (allelic P¼ 0.28 and P¼ 0.31, respec-
tively) or with rs7933235–rs1458836 haplotypes (P¼0.59).
Overall, we observed no association with any of the 65 SNPs
(21 imputed) spanning the UVRAG region (chr11:75,516,
212-75,860,281).
VDR
In 31 GV cases and 33 controls from Romania, Birlea et al.
(2006) reported an association with the VDR restricted
fragment length polymorphism rs7975232 (allelic P¼0.11,
genotypic P¼ 2.9E-02). In this study, we observed no
association with rs7975232 (allelic P¼ 0.26, genotypic
P¼0.31), and meta-analysis was also not significant (meta-
P¼0.19, OR¼ 1.04). Overall, we observed no association
with any of the 58 SNPs (34 imputed) spanning the VDR
region (chr12:48,230,322-48,308,814).
XBP1
Spritz et al. (2004) detected linkage of GV to microsatellites
at 22q11–q11.22 in non-Hispanic white families, and Liang
et al. (2007) at 22q12 in Chinese families. Ren et al. (2009)
tested XBP1 as a positional/biological candidate gene within
the linkage interval, detecting association of SNP rs2269577
in 3 independent Han Chinese cohorts: 319 cases and 294
controls (P¼ 7.0E-03, OR¼ 1.36), 365 cases and 404
controls (P¼8.0E-03, OR¼1.31), and 1,402 cases and
1,288 controls (P¼ 3.0E-03, OR¼ 1.18). In this study, we
observed association of GV with rs2269577 (P¼7.5E-04,
OR¼1.17) and with 21 additional SNPs of a total 39
examined (32 imputed) spanning the XBP1 region
(chr22:29,154,237-29,219,122) (Supplementary Figure S2C
online). Meta-analysis of rs2269577 data from the three
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Chinese cohorts and the current study (Table 2) showed
a consistent high-risk allele across all four studies and strong
evidence of association (meta-P¼ 9.5E-09, OR¼1.21) with
GV, with improved significance compared with meta-
analysis of just the three Chinese studies (P¼2.24E-06,
OR¼1.24).
In the current data set, the lowest P-value across the XBP1
region was for SNP rs6005863 (P¼3.6E-04, OR¼1.17),
located 35 kb upstream of the gene and correlated with
rs2269577 (D 0 ¼0.96, r2¼0.58) (Supplementary Figure S2C
online). Logistic regression analysis of the seven most
significant SNPs showed that the model including
rs6005863 significantly (Po1.5E-03) improved models that
included any of the six other markers, whereas the model
including rs6005863 was not improved by inclusion of any
of six other markers (namely, rs5752809, rs7287806,
rs5762788, rs6005881, rs5762795, and rs2269577). Taken
together, these findings support the association of GV with
XBP1, possibly with the same causal variant in both non-
Hispanic whites and Han Chinese.
DISCUSSION
We analyzed SNP data for 33 GV candidate genes in a large
non-Hispanic white case–control data set that was subjected
to stringent data and population quality control and adjust-
ment for population stratification in our previous GWAS (Jin
et al., 2010a, b). This resource provides 80% power to detect
significant association with common alleles at ORs in the
range 1.20–1.25 across a wide range of allele frequencies.
We found evidence of primary genetic association with
GV for only three of the candidate genes tested, FOXP3,
TSLP, and XBP1, all of which met the Bonferroni-corrected
significance thresholds adjusted on the basis of both the
number of genes (0.05/33) and the number of LD blocks
(0.05/80) tested, although with marginal significance. Never-
theless, the meta-analysis provided strong support for the
association of GV with XBP1 (meta-P¼9.5E-09, OR¼1.21),
with the pattern of associated SNPs indicating that the same
causal allele may exist in both the Chinese and the non-
Hispanic white populations. In contrast, association of GV
with SNPs in the TAP1-PSMB8 region of the MHC seems to
derive from LD with primary association signals in the MHC
class I and class II regions. Furthermore, as suggested by
several previous studies, the apparent association of GV with
CTLA4 seems to be secondary, driven by primary association
of CTLA4 with other autoimmune diseases that are epide-
miologically associated with GV.
We also subjected the SNP data to permutation analysis to
assess whether the observed P-values were truly significant.
The permutation analysis of SNP data for individual
genes generally supported significance for FOXP3
(rs3761547, P¼ 3.3E-02; rs11798415, P¼5.6E-03), TSLP
(rs764916, P¼5.9E-03), and XBP1 (rs2269577, P¼1.8E-02;
rs6005863, P¼8.0E-03). However, combined permutation
analysis of SNP data for all 33 genes studied failed to support
the significance of any of the observed results. This may
indicate that the actual number of total LD blocks represented
is much greater than 80, and a more conservative Bonferroni-
adjusted significance threshold would be more appropriate.
Alternatively, the combined permutation analysis may itself
be too conservative, as several of the genes tested are quite
large (and thus are represented by a large number of SNPs)
and have only questionable status as valid biological
candidate genes in the first place.
Finally, we observed no evidence of association of GV
with SNPs tagging 28 of the 33 candidate genes tested: ACE,
AIRE, CAT, CD4, CLEC11A, COMT, C12orf10, DDR1,
EDN1, ESR1, FAS, FBXO11, FOXD3,GSTM1, GSTT1, IL1RN,
IL10, KITLG, MBL2, NFE2L2, PDGFRA-KIT, PTGS2, STAT4,
TGFBR2, TNF, TXNDC5, UVRAG, and VDR. In the case of
FOXD3, this might reflect the involvement of the gene in only
one unusual family with both atypical presentation and
inheritance of GV. In the case of PDGFRA, this might reflect
the inability of association methods to detect rare causal gene
variants. For many of the others, genetic association has
previously only been tested by relatively small studies carried
out in populations other than non-Hispanic whites, and it is
possible that different populations have different causal
variants. Nevertheless, it is widely recognized that small
case–control candidate gene association studies are very
often flawed by statistical fluctuation, inadequate correction
for multiple testing, and population stratification, and that the
great majority of such reported ‘‘associations’’ are therefore
spurious (Hirschhorn et al., 2002; Freedman et al., 2004).
Such studies must thus be interpreted with great caution until
validated by repeated replication or by studies that use more
Table 2. Study-specific and meta-analysis association tests for XBP1 SNP rs2269577
CMH
Study RA No. of cases No. of controls OR (95% CI) P-value P-value* I2
Ren et al. (2009): study 1 C 264 198 1.36 (1.09–1.71) 7.0E-03 —
Ren et al. (2009): replication 1 C 298 274 1.31 (1.07–1.59) 8.0E-03 —
Ren et al. (2009): replication 2 C 1,195 993 1.18 (1.06–1.32) 3.0E-03 —
This study C 896 1,515 1.17 (1.06–1.29) 7.5E-04 —
Meta-analysis C 2,653 2,980 1.21 (1.13–1.29) 9.5E-09 0.407 0
Abbreviations: CI, confidence interval; CMH, Cochran–Mantel–Haenszel analysis of case–control data; OR, odds ratio; RA, risk allel; SNP, single-nucleotide
polymorphism.
P * Cochran Q-test of heterogeneity.
I2 test of inconsistency.
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robust methods. This analysis, by far the largest association
study of GV candidate genes ever carried out, failed to
support the association of most candidate genes reported for
GV. Although our results do not completely exclude the
possible involvement of these genes in disease pathogenesis,
our findings nevertheless underscore the extreme unreliability
of candidate gene studies in identifying true causal genes for
disease susceptibility.
MATERIALS AND METHODS
Samples and genotypes
We used SNP genotype data from the genome-wide screening stage
of the GV GWAS (Jin et al., 2010a, b), comparing genotype data for
33 candidate loci in 1,392 unrelated non-Hispanic white GV cases
with 2,629 non-Hispanic white controls. Details of this case–control
cohort, quality control procedures, and correction of the data set for
population stratification, have been published previously (Jin et al.,
2010a; dbGaP accession number phs000224.v1.p1). All case study
participants provided written informed consent, and the study was
approved by the Institutional Review Board at each participating
center.
Statistical analyses
Association of SNPs within each region was tested by the
Cochran–Armitage trend test using PLINK, version 1.05 (http://
pngu.mgh.harvard.edu/purcell/plink) (Purcell et al., 2007). For each
candidate SNP, we followed the analytical approach reported for each
locus, assuming at least one of trend (allelic test), genotypic, recessive,
dominant, and codominant models. Both OR and 95% confidence
intervals were assessed by logistic regression using PLINK. Analyses of
X-chromosomal SNPs were performed by applying an algorithm that
combines independent allelic tests in males and females (Zheng et al.,
2007); the resulting test statistic Zmfa has an asymptotic X
2 distribution
with one degree of freedom when the Hardy–Weinberg equilibrium
holds in females. Calculations of LD between SNPs were carried
out using Haploview, version 4.1 (http://www.broadinstitute.org/
haploview) (Barrett et al., 2005). For each region, we imputed SNPs
that were not genotyped using MACH 1.0 (http://www.sph.umich.
edu/csg/yli/mach/tour/) (Li et al., 2006), based on HapMap Phase II
and III data; all imputed SNPs had rsq values 40.3. Power
calculations for individual studies were performed using the genetic
power calculator (Purcell et al., 2003). Meta-analysis was performed
by the Mantel–Haenszel method assuming a fixed effects model,
assessing heterogeneity across studies using the Q- and I2-statistics,
where appropriate. We applied stepwise logistic regression analysis
within regions showing association with GV to distinguish indepen-
dent associations from secondary associations due to LD, assuming a
multiplicative effect for the high-risk allele of each SNP (Cordell and
Clayton, 2002), using STATA, version 10.0 (http://www.stata.com).
Combined permutation analysis (10,000 iterations) of 30 of the loci
tested (MHC loci TAP1-PSMB8, TNF, and DDR1 were not included
because of complex patterns of LD within the MHC), and permutation
tests of each individual locus were performed using the ‘‘max T perm’’
algorithm implemented in PLINK.
Analyses of candidate genes
Using the non-Hispanic white genome-wide GV case–control data set
(Jin et al., 2010a, b), we analyzed 32 genomic regions containing
previously reported candidate genes for GV (ACE, AIRE, CAT, CD4,
CLEC11A, COMT, CTLA4, C12orf10, DDR1, EDN1, ESR1, FAS,
FBXO11, FOXD3, GSTM1, GSTT1, IL1RN, IL10, KITLG, MBL2,
NFE2L2, PDGFRA-KIT, PTGS2, STAT4, TAP1-PSMB8, TGFBR2, TNF,
TSLP,TXNDC5, UVRAG, VDR, and XBP1), as well as FOXP3 as a
previously unreported candidate gene. For each region, we analyzed
the candidate SNP, as well as neighboring SNPs spanning 10kb
upstream and 5kb downstream of the gene (based on NCBI build 37).
Associations were assessed using a gene-wise Bonferroni-adjusted
significance threshold of Po1.52E-03 (0.05/33) and an LD block-wise
Bonferroni-adjusted significance threshold of Po6.25E-4 (0.05/80).
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